Investor Relations

Overview

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: lefamulin, recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

Monday September 9, 2019 9:55 AM EDT
Morgan Stanley 17th Annual Global Healthcare Conference

Monday August 19, 2019 4:30 PM EDT
Nabriva Therapeutics Corporate Update

Tuesday August 13, 2019 9:15 AM EDT
2019 Wedbush PacGrow Healthcare Conference

SEC Filings

Filing date Description Form Filing Group View

Report of unscheduled material events or corporate event

8-K
Current Reports
View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
View HTML

Investor Contacts

E-mail: IR@nabriva.com